Tag
Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.
TAPIS subgroup analysis reveals that ticagrelor-aspirin combined with thrombolysis may improve outcomes in moderate ischemic stroke patients with multiple acute infarcts, without increasing hemorrhage risk, suggesting infarct pattern as a p
This study evaluates the eligibility of children with acute ischemic stroke (AIS) for thrombolysis with tPA, revealing only 19% potential eligibility under current guidelines, and highlights opportunities to reconsider treatment in small-ve
The ENCHANTED trial post hoc analysis reveals body weight does not alter alteplase dose effectiveness in acute ischemic stroke, but low body weight independently predicts poorer outcomes without increased hemorrhagic risk.
This retrospective analysis reveals that standard antiplatelet therapy may reduce mortality compared to thrombolysis in acute spontaneous spinal cord infarction, highlighting the need for cautious therapeutic decisions pending stronger evid
Secondary analysis of TEMPO-2 trial data reveals intracranial hemorrhage in minor stroke patients increases 90-day mortality risk threefold, with higher hemorrhage rates in tenecteplase-treated patients despite most bleeds being non-symptom
The BRAVO study provides critical evidence that while IV thrombolysis improves recovery in isolated vertebral artery occlusion, endovascular treatment may increase risks unless reserved for severe cases.
The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high
The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptoma
The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal
Recent multi-site randomized evidence demonstrates that adding intravenous argatroban or eptifibatide to standard thrombolysis within 3 hours of stroke onset does not improve functional recovery and is associated with increased mortality, i
A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved func
THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben
Telestroke evaluation increases thrombolysis rates but is associated with longer treatment times and delays in patient transfers in acute ischemic stroke, highlighting the need to address modifiable treatment delays.
The HOPE trial demonstrates that intravenous alteplase administered 4.5 to 24 hours after ischemic stroke onset improves functional independence in patients with salvageable brain tissue, despite increased risk of symptomatic intracranial h
A meta-analysis of over 2000 stroke patients found that intravenous thrombolysis (IVT) before endovascular treatment (EVT) modestly increases intracranial hemorrhage (ICH) risk, especially in patients with elevated glucose and blood pressur
